-transparent.png){kind=logo}
We produced human-human hybridomas by fusing lymph node lymphocytes of breast cancer patients with a fusion partner, HO-323 cells, in the presence of 50% polyethylene glycol, and screened hybridomas producing monoclonal antibody (MoAb) reactive to a breast cancer cell line, MCF-7. Among 11 hybridomas secreting IgM reactive to MCF-7, four hybridomas (H15A3, H15F2, K15B4, and K15C3) produced IgM reacting specifically to breast cancer cell lines (MCF-7 and HBC-5). Among them, H15A3 proliferated in a serum-free (RDF) medium supplemented with insulin, transferrin, ethanolamine, selenium, and endothelial cell growth supplement, as fast as in 10% FCS-RDF medium. According to transfer blotting analysis, the H15F2 MoAb reacted with a 40,000 dalton antigen in MCF-7 cells.
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
June 1988,
Immunology letters,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
March 1981,
Proceedings of the National Academy of Sciences of the United States of America,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
January 1985,
Developments in biological standardization,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
April 1989,
Hybridoma,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
December 1980,
Nature,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
January 1987,
Cancer investigation,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
December 1987,
Hybridoma,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
August 1984,
Blood,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
May 1987,
Scandinavian journal of immunology,
K Aihara, and
K Yamada, and
H Murakami, and
Y Nomura, and
H Omura
January 1985,
Immunology letters,
